List of Celgene patents

Patents where

Current Assignee

Name

Celgene

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11583536 Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use	Patent 11583536 was granted and assigned to Celgene on February, 2023 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	11583536	February 21, 2023
‌ US Patent 10272117 Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders	Patent 10272117 was granted and assigned to Celgene on April, 2019 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	10272117	April 30, 2019
‌ US Patent 11626210 Digital health prognostic analyzer for multiple myeloma mortality predictions	Patent 11626210 was granted and assigned to Celgene on April, 2023 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	11626210	April 11, 2023
‌ US Patent 10357489 Antiproliferative compounds and methods of use thereof	Patent 10357489 was granted and assigned to Celgene on July, 2019 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	10357489	July 23, 2019
‌ US Patent 11504378 Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same	Patent 11504378 was granted and assigned to Celgene on November, 2022 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	11504378	November 22, 2022
‌ US Patent 7091353 Isoindole-imide compounds, compositions, and uses thereof	Patent 7091353 was granted and assigned to Celgene on August, 2006 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	7091353	August 15, 2006
‌ US Patent 7147626 Cord blood and placenta collection kit	Patent 7147626 was granted and assigned to Celgene on December, 2006 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	7147626	December 12, 2006
‌ US Patent 10589915 Nested packaging for pharmaceutical products, and methods of distributing pharmaceutical products using same	Patent 10589915 was granted and assigned to Celgene on March, 2020 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	10589915	March 17, 2020
‌ US Patent 8012997 Isoindole-imide compounds, compositions, and uses thereof	Patent 8012997 was granted and assigned to Celgene on September, 2011 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	8012997	September 6, 2011
‌ US Patent 9611465 Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell	Patent 9611465 was granted and assigned to Celgene on April, 2017 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	9611465	April 4, 2017
‌ US Patent 7141018 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Patent 7141018 was granted and assigned to Celgene on November, 2006 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	7141018	November 28, 2006
‌ US Patent 8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Patent 8626531 was granted and assigned to Celgene on January, 2014 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	8626531	January 7, 2014
‌ US Patent 7576104 Isoindole-imide compounds, compositions, and uses thereof	Patent 7576104 was granted and assigned to Celgene on August, 2009 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	7576104	August 18, 2009
‌ US Patent 8673939 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Patent 8673939 was granted and assigned to Celgene on March, 2014 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	8673939	March 18, 2014
‌ US Patent 7470723 Diphenylethylene compounds and uses thereof	Patent 7470723 was granted and assigned to Celgene on December, 2008 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	7470723	December 30, 2008
‌ US Patent 9101622 Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone	Patent 9101622 was granted and assigned to Celgene on August, 2015 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	9101622	August 11, 2015
‌ US Patent 8735428 Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Patent 8735428 was granted and assigned to Celgene on May, 2014 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	8735428	May 27, 2014
‌ US Patent 9101621 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation	Patent 9101621 was granted and assigned to Celgene on August, 2015 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	9101621	August 11, 2015
‌ US Patent 11529339 Combination therapy for the treatment of cancer	Patent 11529339 was granted and assigned to Celgene on December, 2022 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	11529339	December 20, 2022
‌ US Patent 8722647 Methods for treating amyloidosis using 4-(amino)-2-(2,6-Dioxo(3-piperidyl))- isoindoline-1,3-dione	Patent 8722647 was granted and assigned to Celgene on May, 2014 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	8722647	May 13, 2014
‌ US Patent 8648095 Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor	Patent 8648095 was granted and assigned to Celgene on February, 2014 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	8648095	February 11, 2014
‌ US Patent 7968569 Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione	Patent 7968569 was granted and assigned to Celgene on June, 2011 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	7968569	June 28, 2011
‌ US Patent 8198262 Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione	Patent 8198262 was granted and assigned to Celgene on June, 2012 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	8198262	June 12, 2012
‌ US Patent 8207200 Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione follow by autologous stem cell transplantation	Patent 8207200 was granted and assigned to Celgene on June, 2012 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	8207200	June 26, 2012
‌ US Patent 7468446 Substituted heterocyclic compounds and uses thereof	Patent 7468446 was granted and assigned to Celgene on December, 2008 by the United States Patent and Trademark Office.		Celgene	United States Patent and Trademark Office	7468446	December 23, 2008

...

Results per page:

423 results

0 selected

423 results

0 selected